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Resumo 
 O cancro da bexiga é um cancro urológico comum e a maioria tem origem no 
urotélio. Pacientes com risco intermediário e alto de recidiva / progressão do cancro da 
bexiga são tratados com instilação intravesical com Bacillus Calmette-Guérin (BCG), no 
entanto, aproximadamente 30% dos pacientes não respondem ao tratamento. No momento, 
não há biomarcadores para prever o resultado do tratamento e uma identificação precoce 
dos pacientes por terapias alternativas. 
 O tratamento inicia uma cascata de citocinas responsáveis pelo recrutamento de 
macrófagos para o local do tumor que têm mostrado influenciar o resultado do tratamento. 
A terapia eficaz ao BCG necessita de ativação precisa da via imune Th1 associada com 
polarizados em macrófagos M1. No entanto, tumor-associated macrophages (TAMs) 
assumem um fenótipo M2 imunoregulador, tanto imunossupressivo ou angiogénico, que 
interferem em diferentes maneiras com a resposta imunológica antitumoral induzida por 
BCG. O macrófago M2 é influenciado por diferentes microambientes no estroma e do 
tumor. Em particular, o grau de hipoxia é responsável pelo recrutamento e diferenciação 
dos macrófagos para o fenótipo angiogénico M2 e pode estar relacionado com a resposta 
ao tratamento. No entanto, nem os fenótipos de macrófagos, nem a influência da 
localização e hipoxia foram abordados em estudos anteriores. 
 Assim, este trabalho é dedicado ao estudo da influência de TAMs, em particular do 
fenótipo M2 tendo em conta a sua localização (estroma ou tumor) e o grau de hipoxia no 
tumor (baixa ou alta) em resultado do tratamento com BCG. 
 O estudo incluiu 99 pacientes com cancro da bexiga tratados com BCG. Os tumores 
ressecados antes do tratamento foram avaliados usando imunohistoquímica para os 
antigénios CD68 e CD163, que identificam um marcador de linhagem de macrófagos e um 
receptor específico da superfície celular M2 polarizado, respectivamente. A hipoxia no 
tumor foi avaliada com base na expressão de HIF- 1α. Como principal conclusão, 
observou-se que uma elevada predominância de contagens CD163
+
 de macrófagos no 
estroma de tumores sob baixo nível de hipoxia foi associado com insuficiência da 
imunoterapia BCG, possivelmente devido ao seu fenótipo imunossupressor. Este estudo 
reforça ainda mais a importância do microambiente tumoral na modulação das respostas ao 
BCG. 
Palavras-chave: Cancro da bexiga, Imunoterapia Bacillus Calmette-Guérin, Tumor-Associated 
Macrophages (TAMs), Macrófagos com fenótipo M2 
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Abstract 
 Bladder cancer is a common urologic cancer and the majority has origin in the 
urothelium. Patients with intermediate and high risk of recurrence/progression bladder 
cancer are treated with intravesical instillation with Bacillus Calmette-Guérin, however, 
approximately 30% of patients do not respond to treatment. At the moment, there are no 
accepted biomarkers do predict treatment outcome and an early identification of patients 
better served by alternative therapeutics. 
 The treatment initiates a cascade of cytokines responsible by recruiting 
macrophages to the tumor site that have been shown to influence treatment outcome. 
Effective BCG therapy needs precise activation of the Th1 immune pathway associated 
with M1 polarized macrophages. However, tumor-associated macrophages (TAMs) often 
assume an immunoregulatory M2 phenotype, either immunosuppressive or angiogenic, 
that interfere in different ways with the BCG induced antitumor immune response. The M2 
macrophage is influenced by different microenvironments in the stroma and the tumor. In 
particular, the degree of hypoxia in the tumors is responsible by the recruitment and 
differentiation of macrophages into the M2 angiogenic phenotype, suggested to be 
associated with the response to treatment. Nevertheless, neither the macrophage 
phenotypes present nor the influence of localization and hypoxia have been addressed in 
previous studies.   
 Therefore, this work devoted to study the influence of TAMs, in particular of the 
M2 phenotype taking into account their localization (stroma or tumor) and the degree of 
hypoxia in the tumor (low or high) in BCG treatment outcome.   
 The study included 99 bladder cancer patients treated with BCG. Tumors resected 
prior to treatment were evaluated using immunohistochemistry for CD68 and CD163 
antigens, which identify a lineage macrophage marker and a M2-polarized specific cell 
surface receptor, respectively. Tumor hypoxia was evaluated based on HIF-1α expression. 
As a main finding it was observed that a high predominance of CD163
+
 macrophage 
counts in the stroma of tumors under low hypoxia was associated with BCG 
immunotherapy failure, possibly due to its immunosuppressive phenotype. This study 
further reinforces the importance the tumor microenvironment in the modulation of BCG 
responses. 
 Keywords: Bladder Cancer, BCG Imunotherapy, Tumor-Associated Macrophages (TAMs), M2 
macrophages phenotype  
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1. Bladder Cancer 
 Bladder cancer (BC) is a common urologic cancer and the majority has origin in the 
urothelium. BC has the highest recurrence ratio of any malignancy.(1) The mean age of 
diagnosis is around 65 years. It is 3 times more common in men than in women, but has a 
worse prognosis in women.(2) 
 BC is the fifth most common cancer in the United States and one of the ten 
deadliest. It ranks fifth among all cancers in total costs, almost $3 billion annually, and has 
a wide effect on quality of life for survivors and their families.(3)  
 Risk factors that are normally associated with the development of bladder cancer 
include smoking, occupational exposure to chemicals, chronic infection and 
chemotherapeutic agents such as cyclophosphamide.(2) Smoking increases about 4 times 
the probability of developing bladder cancer, and after quitting smoking probability takes 
about 20 years to decrease or return to normal.(2) It is thought that exposure to carcinogenic 
chemicals are the major responsible for BC in men in Europe.(2)  
 The early, non-invasive diagnosis of BC is very difficult to obtain due to its 
specificity and the absence of specific markers. Hematuria is the first symptom and occurs 
in 85% of patients. However, only 7% of patients with hematuria have malignant tumors of 
the genitourinary system. Currently, the American Urological Association (AUA) and the 
European Association of Urology (EAU) recommends a combined diagnostic of a 
cystoscopy and cytology of cells obtained from bladder washing to achieve an accurate 
diagnosis.(3) 
 Cystoscopy is considered to be effective for detecting papillary tumors,(2) while the 
urine cytology is highly specific for the presence of high grade tumors or carcinoma in situ 
(CIS), however, the sensitivity is lower for low grade tumors. Positive urinary cytology can 
indicate an urothelial tumor anywhere in the urinary tract, from the calyx to the ureters, 
bladder and proximal urethra.(1, 4) 
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 Approximately 75% to 85% of all BC are Non-Muscle invasive Bladder Cancer 
(NMIBC), CIS and superficial papillary confined to the mucosa or submucosa (Ta/T1). 
The bladder tumors which invades submucosa, mucosa, muscularis or adjacent organs 
(stage T2 or higher) are classified as Muscle Invasive Bladder Cancer (MIBC).(3,5)  
 CIS is a poorly differentiated carcinoma confined to epithelium with an intact 
basement membrane.(2) It can exist alone, although is usually present in association with 
other bladder tumors (90%).(1) Despite, CIS non-invasive nature it has a poorer prognosis 
than other superficial tumors, about 60% of patients progress to muscle-invasive disease 
over 5 years if left untreated.(2) Papillary tumors, confined to the mucosa, are classified as 
stage Ta according to the TNM system. Tumors that have invaded the lamina propria are 
classified as stage T1. Ta and T1 are grouped under the heading of non-muscle-invasive 
bladder cancer for therapeutic purposes.(4)   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 Figure 1 – TNM staging of transitional cell carcinoma bladder cancer based on 
invasion (T). (Adapted from (2)) 
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 The first-line treatment of a BC is transurethral resection of the bladder tumor 
(TURBT), comprehending a representation of the muscularis propria to ensure a total and 
a proper resection, and more precise staging.(1, 3, 5) After TURBT, patients are reviewed at a 
multidisciplinary team meeting and assigned a risk category.(1)  
 The NMIBC risk classification divides patients into low risk, intermediate risk and 
high-risk categories for recurrence and progression.(1) Low risk is defined as solitary, 
primary low grade Ta tumors; intermediate risk as multiple or recurrent low grade tumors; 
and high risk as any T1and/or CIS.(6) The scoring system is based on the six most 
significant clinical and pathological factors: number of tumors, tumor size, prior recurrence 
rate, T-category, presence of concurrent CIS and tumor grade.(4) 
 Patients with low risk disease are kept under cystoscopy surveillance. For patients 
with recurrent low grade disease or intermediate/high risk disease adjuvant intravesical 
therapy is recommended.(1) The gold standard treatment for intermediate/high risk patients 
is intravesical instillations with Bacillus Calmette-Guérin (BCG).(1) However, 30–50% of 
patients fail to respond, and 15% show progression to muscle-invasive disease. In these 
cases, radical cystectomy is the treatment to follow.(7) 
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2. Bacillus Calmette-Guérin (BCG) 
 
 Bacillus Calmette-Guérin (BCG) is an attenuated strain of Mycobacterium bovis 
that is used in bladder cancer as treatment, and instilled intravesically.(1)  The key element 
of the BCG antitumor activity, lies in its ability to promote a strong local immune cell 
response(8), still the exact mechanism remain unknown.(5) 
 The immune complex cascade begins with the initial adhesion and internalization 
of mycobacteria to the urothelium and proceeds through the secretion of cytokines from 
urothelial and immune cells, a process that recruits a wide variety of inflammatory cells 
(neutrophils, monocytes, T cells) and cytokines to the tumor site and surroundings.(8) 
 Intravesical BCG immunotherapy is a standard treatment for CIS disease and high-
grade or highly recurrent superficial tumors.(1) Mitomycin C (MMC) chemotherapy is 
another treatment that is recommended in patients with low and intermediate risk, where 
both agents are equally effective in reduction of recurrence but MMC has lower toxicity.(9) 
 In a meta-analysis of 7 studies comparing TURBT alone versus TURBT plus 
intravesical BCG, has shown that BCG significantly reduces recurrence in 12% and the 
chances of progression are reduced in 24%.(4) Another meta-analysis with 24 studies 
mentions a reduction in 27% the chances of progression when the patients received 
TURBT plus intravesical BCG.(1) 
 However, BCG immunotherapy for bladder cancer has its limitations. Even though 
of severe adverse effects are rare (<5%), approximately 90% of patients experience light 
cystitis and about one fifth are unable to tolerate BCG therapy. Various approaches have 
been tried in efforts to reduce side effects, for example the use of different dosages.(9, 10) 
 Induction BCG therapeutic scheme generally begin at least two weeks after 
TURBT to allow the healing of the urothelium and to reduce the risk of systemic side 
effects.(8) BCG therapy consists of a single course of six weekly intravesical instillations. 
The extension of treatment (maintenance immunotherapy) is used to increase efficacy.(11) 
The maintenance regimen consists in of three weekly instillations at 3 months, 6 months, 
and then every 6 months up to 3 years. (6, 8, 12) The adoption of maintenance schedule has 
been a crucial factor for improving BCG efficacy.(6,8)  
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 A prospective study by the Southwest Oncology Group (SWOG) was performed to 
evaluate the efficacy of additional maintenance schedule following the initial induction 
cycle. This study demonstrated a significantly reduction of tumor recurrences in favor of 
the additional maintenance treatment. Furthermore, recent meta-analyses demonstrated that 
bladder tumor progression can only be prevented when an additional BCG maintenance 
(mBCG) therapy is applied.(12) In 20 trials analyzed, in some of which the mBCG scheme 
was used, it was observed a 37% reduction in the odds of progression.(4) Supposing that 
maintenance therapy is necessary for optimal efficacy, the problem of BCG toxicity 
becomes more significant. As a result of the more pronounced side effects of BCG, there is 
still hesitancy about the use of mBCG.(4) More than 70% of patients develop local 
symptoms and up to 37% develop systemic symptoms with maintenance therapy with 
BCG.(1) 
 BCG is currently considered the most effective intravesical agent for preventing 
recurrence in NMIBC, however 30-50% of patients do not respond, and 15% have the 
progression to invasive muscle disease.(7, 8, 13) When BCG immunotherapy fails, immediate 
radical cystectomy is recommended to reduce the risk of tumor progression.(6, 9) 
 At this moment, no valid prognostic markers have been found to predict clinical 
responses to BCG or to identify patients who may progress after BCG treatment. While 
studies on the mechanism of BCG provide several promising candidates such as 
interleucine-2 (IL-2), IL-8, IL-12, inflammatory chemokines (macrophages), none of these 
parameters are considered sufficiently consistent for daily practice. However, it is believed 
that immunological prognostic markers may yield promising clinical value in the context 
of predicting BCG immunotherapy outcome.(12) 
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 3. Tumor-Associated Macrophages (TAM) 
 
 TAMs are originated from circulating blood monocytes recruited into the tumor. 
Their recruitment and survival in situ are directed by cytokines that interact with tyrosine 
kinase receptors.(14) The strategic location of TAMs, suggests that these cells are important 
regulators of anti-tumor immunity. Phenotypical characterization of TAMs is crucial to the 
understanding of tumor-derived signals guiding polarization of innate and adaptive 
immunity in cancer and to the identification of molecular mechanisms.(15) 
 The capability to express diverse functional programs in response to different 
micro-environmental signals is a biological feature of macrophages, which is typically 
demonstrated in pathological conditions such as infections and cancer.(15) TAMs can 
regulate the growth of various cancers, positively or negatively, because of their 
implication in defense against mycobacteria.(13, 14) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2 – Monocytes differentiation in polarized macrophages. M1 and M2 subsets 
diverge in terms of phenotype and functions. (Adapted from (15))  
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 The classical or M1 macrophages are recognized as a unique program of anti-
microbial response. In contrast, M2 macrophages are known for high scavenging ability, 
promoting tissue repair, angiogenesis and tumor progression.(15) Only recently it was 
recognized anti-inflammatory molecules that can induce different responses in M2 
macrophage activation. These molecules are, for example IL-4 and IL-10. This distinction 
between M1 and M2 macrophages do not represent very well the different states of 
activation of macrophages but a simplified way to see the two extremes of polarization of 
macrophages.(15, 16) 
 The M1 macrophages activation occurs in response to microbial products and are 
characterized by a high capacity to present antigens. They produce high levels of IL-12 
which consequently leads to the activation of a polarized type I response (Th1). They also 
produces toxic intermediates, such as nitric oxide and reactive oxygen species.(17) Thus M1 
macrophages may be considered effectors cells enhancers that act against microorganisms 
and tumor cells, producing large amounts of pro-inflammatory cytokines. On the other 
hand, the response of M2 macrophages, depend on the polarized type II response (Th2), 
adaptive immunity. They promote angiogenesis and tissue repair and remodeling, and 
express low levels of IL-12 and high levels of IL-4 and IL-10. (15, 16) 
  The unbalance between of M1 and M2 cell number may lead to pathological events. 
An M1 excess may induce chronic inflammatory diseases, while an uncontrolled number 
of M2 may lead to severe immune suppression.(18) 
 Supportive to the macrophage balance hypothesis, macrophages assume different 
functional activation states depending on the microenvironment to which they are exposed. 
In the tumor microenvironment, TAMs assume an immunoregulatory M2 phenotype 
characterized by the expression of immunosuppressive molecules such as IL-10.(18, 19) 
 Tumors are mostly composed of proliferating tumor cells and stromal cells, with 
endothelial cells, inflammatory cells and fibroblasts. It is well-establish that TAMs plays a 
crucial role in tumor growth.(20) In tumor promoting biology, TAMs assume different 
phenotypes activating mechanisms, such as production of immunosuppressive molecules, 
angiogenesis and production of growth factors and proteases linked favorable to tumor 
invasion/metastasis.(15, 19, 21) 
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3.1. TAMs and Tumor Growth 
 
 As soon as monocytes reach the tumor mass, they are surrounded by several signals 
able to shape the cells as needed by the tumor.(18) The key factors implicated in the 
recruitment are chemokine CCL2, macrophage colony-stimulating factor (M-CSF) and 
vascular endothelial growth factor (VEGF). As they arrive the tumor, they are enclosed for 
several microenvironmental signals that induce the differentiation to TAMs, so they can 
produce the factors (IL-4, IL-10, Transforming Growth Factor beta (TGF-β)) needed by the 
tumor to growth.(18) 
 TAMs work actively for supporting tumor cell growth by producing M-CSF, 
VEGF, epidermal growth factor (EGF), tumor necrosis factor (TNF-α), matrix 
metalloproteases (MMPs) and IL-1.(18, 22, 23) All these factors contribute to the activation of 
a Th2 response by inhibiting the Th1 response. 
 Another important mechanism performed by TAMs is activation of signal 
transducer and activator of transcription 3 (STAT3) which in turn activates the expression 
of IL-6 that induce the proliferation of tumor cells.(23) 
 
3.2. TAMs and Immunosuppression 
 
 The immunosuppressive functions of TAMs within the tumor can be activated by 
different ways, exhibiting factors with massive potential immunosuppressive that 
consequently inhibits the activity of cytotoxic T cells.(20, 24) Most studies showed that the 
main factors involved in this process are the TGF-β, IL-10, Arginase 1 and CCL.(20) TGF-β 
inhibits the activity of natural killer cells (NK) leading to a poor anti-tumor response. IL-
10, a cytokine produced by TAMs, in large amounts, leading to a suppression of IL-12 and 
thereby inhibiting Th1 response and suppressing the activity of cytotoxic T cells.(20-22) 
Arginase 1 metabolizes producing polyamide and proline which causes dysregulation of 
the T cell receptors that induces the suppression of CD8
+
 T. The chemokines (CCL-2) 
produced by TAMs induce a Th2 response, regulate the flow of T regulatory cells and 
suppress the response of cytotoxic T cells.(20, 21, 23) 
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3.3. TAMs and Angiogenesis 
 
 The process of angiogenesis involves multiple mediators and recruitment of 
different cell types. One of the cells involved are TAMs, which have a positively 
correlation with angiogenesis; increased infiltration of TAMs increased production of 
blood vessels leading to an increase tumor growth.(18, 22) 
 Epidemiological studies indicates that a full macrophage microenvironment will 
foster a more aggressive tumor, and consequently with a high metastatic potential.(20, 21) 
Tumors can’t progress unless they are vascularized. It has been described that TAMs are 
the inducers of neovascularization and support functions.(20)  
 Recent publications have shown that a large number of TAMs are attracted and 
retained in avascular and necrotic areas when they are exposed to tumor hypoxia.(21, 25) 
Hypoxia is defined as a condition where the oxygen concentration is significantly lower 
than in healthy tissues.(26) Hypoxia is one of the most important micro environmental 
phenomen that control the phenotype of macrophages in pathological situations.(20, 25, 27) 
The effect of hypoxic areas exercised on macrophages is applied by a known transcription 
factor the hypoxia-inducible factor (HIF) and its two isoforms HIF-1α and HIF-2.(18, 20, 27) 
 There may be different hypoxic responses depending on profile of gene expression 
of macrophages. One of the possible changes induced by hypoxia in macrophages is the 
expression of cytokines and angiogenic and metastatic genes, VEGF, Platelet-derived 
Growth Factor (PDGF), TGF-β and MMP, as well as pro-inflammatory cytokines such as 
TNF-α.(18, 20, 22, 25, 27) 
 The process of angiogenesis is correlated with an increased macrophage infiltration 
by inhibition the mobility of TAMs, facilitating their accumulation in hypoxic areas.(23, 25) 
The number of TAMs is generally higher in tumors with high levels of hypoxia.(23) 
Macrophages are essential in tumor angiogenesis being performing duties in tissue repair 
and producing essentially VEGF in the avascular and tumor areas.(18, 28) 
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3.4. TAMs and Tumor Invasion and Metastasis 
 
 Studies show that primaries tumors with high counts of TAMs are correlated with 
the early appearance of metastasis.(22) 
 In the beginning, TAMs assist tumor cells in the mobility out of the mass towards 
the blood vessels. And then, TAMs assists cancer invasion helping tumor cells in their 
movement, forming clusters of tumor cells and macrophages. TAMs move alongside the 
tumor cells releasing EGF promoting the invasion of malignant cells.(20) 
 TAMs, also, release TNF-α and MMPs promoting the disruption of the basement 
membrane degrading the proteins of extracellular matrix.(18, 20) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3 – A simplified vision of TAMs in the immunobiology of tumors where 
TAMs display some pro-tumoral functions. 
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4. BCG and Macrophages 
 
 The intravesical instillations of BCG induce a massive local immune response that 
is characterized by the expression of cytokines in urine and bladder wall and also an influx 
of granulocytes and mononuclear (lymphocytes and macrophages) cells. These 
mononuclear cells express activation markers and cellular infiltrates can persist for 12 
months.(29)  
 After BCG being administered it can be internalized by benign cells of the 
urothelium or by tumor cells. After degradation, it induces the formation of antigens which 
are presented at the cell surface.(7, 9) In response to mycobacterial stimulation, urothelial 
cells secrete pro-inflammatory cytokines including IL-1, IL-6, IL-8, IL-12 and TNF-α.(17) 
A few hours after instillation, BCG initiates a complex inflammatory cascade of events. 
The first cells of innate immune response to be released consist of large numbers of 
neutrophils followed by monocytes/macrophages that infiltrate the bladder wall and adding 
characteristic cytokines and chemokines.(17) Released cytokines and chemokines attract 
conventional T lymphocytes, Natural Killer (NK) cells and neutrophils that cause a severe 
immune response leading to the neutralization of the tumor. Dendritic cells and 
macrophages are also capable of exercising anti-tumor effects.(9) These immune cells 
attract CD4
+
T cells, leading to a T helper 1 (Th1) response.(29) Attracted immunocompetent 
cells form granuloma-like structures, dominated by CD4
+
T cells, in the bladder wall.(17) 
Supported by the repeated BCG-instillations, formation of cellular infiltrates and 
granuloma-like structures proceeds for several weeks.(17)  
 The Th1 response, or cell immune response, and Th2 response, or humoral immune 
response, are responsible for different patterns cytokine secretion. Th1 response primarily 
secret IL-2, IL-12, Interferon-gama and TNF- α; the Th2 response secret IL-4, IL-5, IL-6 
and IL-10.(11)  
 Qualitative analyses of the immune response indicate that the effective 
establishment of a Th1-cytokine profile is crucial for mounting an effective antitumor 
response. The importance of the Th1/Th2-dichotomy is further supported by observations 
that high expression levels of immunoregulatory cells like IL-10 stop Th1 responses and 
nullify the therapeutic effect of BCG.(17) BCG immunotherapy also promotes an innate 
immune response, a massive increase in the number of TAMs and lymphocytes have been 
reported in patient’s urine after intravesical BCG therapy.(29)  
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 More recently has been recognized that tumor biology, tumor progression and 
response to therapy depend on various other components of the tumor tissue, the tumor 
microenvironment.(19) These other components include stromal cells, infiltrating leukocytes 
and blood vessels (depending on tumor size), all of which contribute to the so-called tumor 
stroma. TAMs are a major component of the tumor stroma and experimental data suggest 
that TAMs may promote tumor progression.(19) TAMs may directly interfere with the BCG 
induced antitumor immune response and/or they may represent a marker for a tumor 
promoting environment.(18, 19) 
 At the moment, there are no suitable predictive markers of BCG treatment 
response. (7, 30) Recent systematic reviews highlighted that TAMs may have potential as a 
predictive biomarker, since when detected at tumor and surrounding tissue, it can be 
strongly correlated with tumor treatment response.(30) Ayari et al., in 2009, found that a 
higher TAM count in peri-tumoral region was associated with lower recurrence free 
survival and with a high risk of BCG treatment failure.(13) The same was reported for CIS 
tumors treated with BCG by Takayama.(14)  
 That is clear that an immunocompetent host response is mandatory for BCG to 
apply its action.(8) Therefore a superior number of TAMs could stimulate a more efficient 
phagocytosis and elimination of BCG, preventing BCG from inducing a long-term local 
inflammation and consequent anti-tumor effect. By the other hand, Takayama and 
coworkers(14) described that TAMs could interfere directly in BCG treatment response 
through the induction of immunosuppressive cytokines patterns, such as the typical pattern 
of cytokines produced by M2 macrophages (IL-4/IL-10).(14, 30, 31) However, it would be 
necessary to promote further studies in this specific issue to prove the influence of TAMs 
in the immune response to treatment with BCG.(30)  
 Macrophages are the central piece to different immune responses and are clearly 
immunoregulatory cells within the tumor.(21) Several studies suggest that a high number of 
TAMs is essential for tumor growth and progression and consequently related with poor 
prognosis for the patients. Although, in some studies a high number of infiltrating TAMs is 
correlated with better prognosis.(28)  
 The nature of TAMs is an essential point of study. Since it is already widely known 
that M2 macrophages are capable of producing factors and anti-inflammatory cytokines 
Th2 that could down-regulate the response to BCG treatment.(30, 31) 
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Furthermore, macrophages in different localizations may present different 
phenotypes induced by the microenvironment. For  example, oxygen shortage is known to 
promote an accumulation of angiogenic M2-macrophages in tumor hypoxic areas, where 
HIF-1α enhances the expression of VEGF and decreases the production of classical Th2 
cytokines.(25) Despite these observations, the influence of hypoxia in the modulation of 
M2-polarized macrophage distribution in bladder tumors and stroma and its association 
with BCG treatment outcome also remains unevaluated.     
 In resume, a clarification about the expression pattern of M2-macrophages in 
intermediate and high-risk of recurrence bladder tumors and the influence of hypoxia is 
needed to disclose their true predictive value in the context of BCG response.  In this study 
we devoted to this matter by evaluating the overall TAMs (CD68
+
) as well as the M2 
phenotype, based on CD163 expression, in both stroma and tumor areas.  As outlined, we 
correlated our findings with HIF-1α expression to disclose the influence of hypoxia in M2-
macrophage accumulation and treatment outcome.    
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The predominance of M2-polarized macrophages in the stroma of low-hypoxic 
bladder tumors is associated with BCG immunotherapy failure  
ABSTRACT 
Objective: Bacillus Calmette-Guérin (BCG) immunotherapy is the gold standard treatment 
for superficial intermediate/high risk of recurrence or progression bladder tumors. 
However, approximately 30% of patients fail to respond to treatment. Effective BCG 
therapy needs precise activation of the Th1 immune pathway. Tumor-associated 
macrophages (TAMs) often assume an immunoregulatory M2 phenotype and may directly 
interfere with the BCG induced antitumor immune response. Thus, we aim to clarify the 
influence of TAMs, in particular of the M2-phenotype in stroma and tumor areas, in BCG 
treatment outcome.  
Patients and methods: The study included 99 bladder cancer patients treated with BCG. 
Tumors resected prior to treatment were evaluated using immunohistochemistry for CD68 
and CD163 antigens, which identify a lineage macrophage marker and a M2-polarized 
specific cell surface receptor, respectively.  CD68
+
 and CD163
+
 macrophages were 
evaluated within the stroma and tumor areas and high density of infiltrating cells spots 
were selected for counting. Hypoxia, an event known to modulate macrophage phenotype, 
was also accessed through HIF-1α expression. 
Results: Patients in which BCG failed had high stroma-predominant CD163
+
 macrophage 
counts (high stroma but low tumor CD163
+ 
macrophages counts) when compared with the 
ones with a successful treatment (71% vs. 47%; p=0.017). Furthermore, patients presenting 
this phenotype showed decreased recurrence-free survival (log rank, p=0.008) and a clear 
2-fold increased risk of BCG treatment failure was observed in univariate analysis 
(HR=2.343; 95%CI: [1.197-4.587]; p=0,013). Even when adjusted to potential 
confounders, such as age and therapeutic scheme, multivariate analysis revealed 2.6-fold 
increased risk of recurrence (HR=2.627; 95%CI: [1.340-5.150]; p=0.005). High stroma-
predominant CD163
+
 macrophage counts were also associated with low expression of HIF-
1α in tumor areas, whereas high counts of CD163+ in the tumor, presented high expression 
of HIF-1α in tumor nests. 
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 Conclusions: TAMs evaluation using CD163 is a good indicator of BCG treatment 
failure. Moreover, elevated infiltration of CD163
+
 macrophages predominantly in stroma 
areas but not in the tumor may be a useful indicator of BCG treatment outcome, possibly 
due to its immunosuppressive phenotype.  
 
Keywords: Bladder cancer, BCG immunotherapy, Tumor-associated macrophages, CD68, 
CD163 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Macrophages as biomarkers in BCG treatment response in bladder cancer 
 
21 
 
INTRODUCTION 
 Bladder cancer (BC) is the second most common urologic cancer and has the 
highest recurrence ratio of any malignancy. (1) Approximately 75-85% of all BC are non-
muscle invasive (NMIBC), which includes carcinoma in situ (CIS) and papillary tumors 
confined to the mucosa or submucosa (Ta/T1). (1) The NMIBC risk classification divides 
patients into low, intermediate and high-risk categories for recurrence and progression. (1)  
The gold standard treatment for intermediate/high risk patients is intravesical instillations 
with Bacillus Calmette-Guérin (BCG). (1)  However, 30–50% of patients fail to respond, 
and 15% show progression to muscle-invasive disease. In these cases, radical cystectomy 
is the treatment to follow.(2) Intravesical instillations of BCG induce a massive local 
immune response that is characterized by the expression of cytokines in the bladder, as 
well as an influx of granulocytes and mononuclear cells (lymphocytes and macrophages) 
into the tumor areas.(3, 4)  
 Tumor biology, tumor progression and response to therapy are influence by the 
tumor microenvironment.(5, 6) These includes stromal cells, infiltrating leukocytes and 
blood vessels (depending on tumor size), all of which contribute to the so-called tumor 
stroma.(6) Tumor-associated macrophages (TAMs) are a major component of the tumor 
stroma that contributes to tumor progression in several types of cancer.(6, 7)    
Macrophages are polarized in two distinct functional forms, M1 and M2.(6-8) The 
classical or M1 macrophages activate type 1 helper cells (Th1) that have the capability to 
kill pathogens, produce IL-2, IL-12 and pro-inflammatory cytokines that promote 
responses like cytotoxic T-cell activation.(8) In contrast, alternatively-activated M2 
macrophages express low levels of IL-12 and high levels of IL-4 and IL-10, promoting 
Th2 cytokines that inhibit Th1 responses.(7) However, associated to the tumor, M2-
polarized macrophages comprise multiple subtypes that may contribute to 
immunosuppression, angiogenesis, cell invasion and metastasis, depending on the 
microenvironment.(5, 9) Also, cytokines and chemokines released by the tumor may recruit 
and modulate monocyte differentiation into M2-macrophages lineages that may differ from 
those in the stroma.(6, 7)  As such, a detailed evaluation of macrophage phenotypes in both 
the tumor and the stroma as well as their microenvironment is needed to fully understand 
how M2-macrophages influence tumor behavior and ultimately the response to treatment. 
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 The studies presented so far indicate that higher TAM counts are associated with 
lower recurrence free survival and high risk of BCG treatment failure.(10-12) Nevertheless, 
these conclusions were based exclusively on CD68 expression, a macrophage lineage 
marker that does not allow the discrimination between M1 and M2 phenotypes therefore 
adding bias to these observations.(13, 14) Also, patients that respond to BCG commonly 
release large amounts of Th1 cytokines (15),  whereas high levels of Th2 cytokines (i.e. IL-
4 and IL-10) seem to be related with BCG failure.(16) These observations support the idea 
that effective BCG therapy requires precise activation of the Th1 immune pathway.(17, 18) 
However, TAMs assuming an immunoregulatory M2-phenotype release Th2 cytokines that 
may directly interfere with the BCG induced antitumor immune response.(7, 16, 18) Still, no 
direct evidences have been presented supporting the association between higher counts of 
M2-polarized macrophages and the failure of BCG treatment.  
Furthermore, macrophages in different localizations may present different 
phenotypes induced by the microenvironment. For  example, oxygen shortage is known to 
promote an accumulation of angiogenic M2-macrophages in tumor hypoxic areas, where 
HIF-1α enhances the expression of VEGF and decreases the production of classical Th2 
cytokines.(19) Despite these observations, the influence of hypoxia in the modulation of 
M2-polarized macrophage distribution in bladder tumors and stroma and its association 
with BCG treatment outcome also remains unevaluated.     
 In resume, a clarification about the expression pattern of M2-macrophages in 
intermediate and high-risk of recurrence bladder tumors and the influence of hypoxia is 
needed to disclose their true predictive value in the context of BCG response.  In this study 
we devoted to this matter by evaluating the overall TAMs (CD68
+
) as well as the M2 
phenotype, based on CD163 expression, in both stroma and tumor areas.  As outlined, we 
correlated our findings with HIF-1α expression to disclose the influence of hypoxia in M2-
macrophage accumulation and treatment outcome.    
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METHODS 
Cohort of Patients 
 In this study were included 99 formalin fixed paraffin embedded (FFPE) tissues 
from patients treated with transurethral resection of bladder tumor (TURBT) and then 
submitted to BCG immunotherapy in the Urology Department of Portuguese Institute of 
Oncology – Oporto (IPO-Porto), between 1998 and 2006. All patients received induction 
BCG therapy for 6 consecutive weeks, starting 2-3 weeks after surgery (iBCG) and were 
then submitted to mBCG schedule (the one used in our institute is iBCG + maintenance 
protocol with 2-weekly instillations every 3 months during 2 years). The iBCG group 
includes patients treated before the European Association of Urology guidelines  
recommending the mBCG scheme [20] and patients showing significant intolerance to 
long BCG treatment. 
 The average age of the patients was 68 years (range 41-85). The male:female ratio 
was 84:15. The patients were followed every 3 months during the first year, every 6 
months in the second year and every 12 months thereafter by cystoscopy and urine 
cytology. The median follow-up time was 68 months (range:10-163months). 
 Recurrence was defined as the appearance of a tumor after the beginning of the 
treatment, with at least one tumor-free cystoscopy and cytology in-between. BCG failure, 
as opposed BCG success, was defined as patients submitted to BCG treatment with tumor 
recurrence. Finally, recurrence-free survival (RFS) was defined as the period between the 
beginning of the treatment and either recurrence or the most recent tumour-free cystoscopy 
and cytology. All procedures were performed after patient’s informed consent and 
approved by the Ethics Committee of IPO-Porto. All clinicopathological information was 
obtained from patients’ clinical records. All tumour samples were revised by an 
experienced pathologist, regarding 2004 WHO grading criteria. 
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Immunohistochemistry  
 TAMs immunohistochemistry was performed with CD68 antibody (Monoclonal 
Mouse Anti-Human CD68; Clone PG-M1; DAKO) at a dilution of 1:100 in PBS, after 1h 
incubation at 37°C. M2 macrophages were accessed with the CD163 antibody 
(Monoclonal Mouse Anti-Human CD163; Clone 10D6; Novocastra-Leica) at a dilution of 
1:100 in PBS, after overnight incubation at 37°C. Immunohistochemical detections were 
performed using HRP Detection System Kit according to manufacturer’s instructions. 
Diaminobenzidine (Impact Dab, Vector Labs) was used for color development. Hypoxic 
sites were evaluated using HIF-1α antibody (Monoclonal Mouse Anti-Human HIF-1α; 
Clone H1α67; Abcam) at a dilution of 1:50 in PBS, after overnight incubation at 37°C.  
 
Immunohistochemistry Scoring 
 CD68
+
 and CD163
+
 macrophages, infiltrating the stroma and tumor areas were 
counted by two independent observers (LL, DO) and validated by an experienced 
pathologist (TA). Each specimen was screened at low magnification (100x) and the five 
areas with highest number of positively stained cells (hot-spot area) were selected. 
Photographs were taken, at a 400x magnification, with a real area of 0.035 mm
2
, and 
TAMs number was counted. The criteria used for macrophage specific counting were as 
follows: i) cells must present the shape of a macrophage and exhibit the macrophage 
characteristic staining pattern; ii) must present cell nucleus; and iii) be birefringent if the 
size is small;. Macrophages were evaluated in the tumor stroma, which included the 
papillary axis, lymphoid aggregates and stroma, and in tumor islets. Macrophages counts 
were classified as low or high according to their distribution in percentiles. The expression 
of HIF-1α was determined based on percentage of positive cells and stratified in groups 
was as follows: Low (negative or 1-10% nuclear or cytoplasmic staining) and High (10-
50% or >50% nuclear or cytoplasmic staining). 
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Statistical Analysis 
Statistical data analysis was performed using the IBM Statistical Package for Social 
Sciences—SPSS for Windows (version 20.0). Chi-square analysis was used to compare 
categorical variables. Correlation between macrophage counts and clinical variables was 
performed using Spearman rho test. Kaplan-Meier survival curves were used to evaluate 
correlation between TAMs counts and RFS, log-rank statistical test was used for curves 
comparison. Multivariate Cox regression analysis was used to assess the effect of TAMs 
density on the time to recurrence in BCG-treated patients and to adjust for potential 
confounders.  
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RESULTS 
Association of Clinical and clinical characteristics with BCG treatment outcome 
Approximately 42.4% of the patients presented recurrences, with the median 
recurrence time of 38.5 months (range: 10-122). The median follow-up time of the patients 
free of recurrence was 97 months (range: 13-163). 
Table 1 shows the clinicopathologic parameters and its association with treatment 
response and RFS. An association was found between patients’ age and treatment 
response, since 69% of the patients presenting BCG failure were over 65 years when 
compared with 43.9% in the BCG success group (p=0.013). Consequently, patients over 65 
years presented almost a 3-fold increased risk of recurrence (HR=2.763; 95%CI: [1.431-
5.336]; p=0.002). Similarly, patients treated with mBCG presented a 50% risk reduction of 
recurrence (HR=0.500; 95%CI: [0.271-0.919]; p=0.026).  Approximately 70% of the 
patients successfully treated were submitted to mBCG scheme (vs. 45% of the patients 
presenting treatment failure, p=0.021). Interestingly, no association was found between 
treatment outcome and other characteristics such as gender, tumour stage, number, grade 
or size, CIS presence and prior recurrence. 
 
Pattern of macrophage infiltration 
 We started by evaluating the localization of macrophages within tumor specimens. 
We observed the presence of CD68
+
 and CD163
+
 macrophages in both tumor stroma and 
in tumor islets. The tumor stroma included the papillary axis, lymphoid aggregates and 
stroma. The mean count of CD68
+ 
macrophages was 33 within stroma and 13 within tumor 
while for CD163
+
 macrophages within stroma and tumor was, respectively, 24 and 7. The 
mean ratio of CD163
+
/CD68
+
 macrophages was 51.3% in the tumor and 24.6% in the 
associated stroma. A moderate to strong CD68
+
 macrophage stroma infiltration was 
observed in 46% of the tumors while only 4% of cases had none CD68
+
 macrophage 
staining in tumor nest. A high CD163
+
 macrophages stroma infiltration was observed in 
15% tumors while only 8% of tumors presented no CD163 staining in tumor nests. 
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 Table 1 – Relation between patients clinical and tumour characteristics and response to 
BCG treatment and time to recurrence. 
 
Variables Total Responders Non-
Responders 
HR [95% CI] p* 
 n (%) n (%) n (%)   
Age      
<65 years 45 (45.5) 32 (56.1) 13 (31.0) 1.0  
≥65 years 54 (54.5) 25 (43.9) 29 (69.0) 2.763 [1.431-5.336] 0.002 
Sex      
Male 84 (84.8) 46 (80.7) 38 (90.5) 1.0  
Female 15 (15.2) 11 (19.3) 4 (9.5) 0.526 [0.187-1.478] 0.223 
Stage      
Ta 40 (40.4) 22 (38.6) 18 (42.9) 1.0  
T1 59 (59.6) 35 (61.4) 24 (57.1) 0.961 [0.521-1.773] 0.899 
Grade      
Low 39 (39.4) 24 (42.1) 15 (35.7) 1.0  
High 60 (60.6) 33 (57.9) 27 (64.3) 1.410 [0.749-2.654] 0.287 
Size (cm)      
<3 64 (65.3) 36 (63.2) 28 (68.3) 1.0  
≥3 34 (34.7) 21 (36.8) 13 (31.7) 0.760 [0.393-1.470] 0.416 
Tumor number      
Unifocal 45 (45.5) 29 (50.9) 16 (38.1) 1.0  
Multifocal 54 (54.5) 28 (49.1) 26 (61.9) 1.729 [0.924-3.235] 0.087 
CIS      
No 92 (92.9) 53 (93.0) 39 (92.9) 1.0  
Yes 7 (7.1) 4 (7.0) 3 (7.1) 0.944 [0.291-3.056] 0.923 
Recurrence Status      
Primary 51 (51.5) 33 (57.9) 18 (42.9) 1.0  
    Recurrent 48 (48.5) 24 (42.1) 24 (57.1) 1.562 [0.847-2.881] 0.153 
BCG schedule      
iBCG 41 (41.4) 18 (31.6) 23 (54.8) 1.0  
mBCG 58 (58.6) 39 (68.4) 19 (45.2) 0.500 [0.271-0.919] 0.026 
 
HR: Hazard Ratio; CI: Confidence Interval; CIS: Carcinoma in situ. 
* 
: Wald test 
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Correlation between clinical characteristics and CD68
+
 and CD163
+
 macrophage counts 
The correlation between clinical variables and the macrophages counts are 
indicated in Table 2. Our results evidenced that CD68
+
 and CD163
+
 macrophages counts 
within stroma and tumor were correlated with higher stage, grade and tumor size (Table 2, 
p<0.05). Similarly, higher counts of CD68 and CD163 within tumor were observed in 
primary tumors (Table 2, p<0.05). Interestingly, higher CD163/CD68 ratios in tumor nests 
were associated with the CIS presence (Table 2, p <0.05). No correlations were found 
regarding gender, age and multifocality. 
  
 Table 2 – Correlation between clinical parameters and CD68+ and CD163+ macrophages 
counts, in tumor stroma and tumor nest. 
 
CIS: Carcinoma in situ. 
P value : Chi-square test 
 
 
 
 
 
 
 
 
CD68
+
 macrophages counts CD163
+
 macrophages counts CD163
+
/CD68
+
 macrophage ratio 
Tumor Stroma Tumor Nest Tumor Stroma Tumor Nest Tumor Stroma Tumor Nest 
Correlation 
coefficient 
P value 
Correlation 
Coefficient 
P value 
Correlation 
Coefficient 
P value 
Correlation 
Coefficient 
P value 
Correlation 
Coefficient 
P value 
Correlation 
Coefficient 
P value 
Age 0.026 0.802 -0.030 0.770 0.012 0.906 0.034 0.735 -0.015 0.884 0.014 0.897 
Sex -0.046 0.649 0.129 0.204 -0.066 0.519 0.166 0.101 -0.028 0.786 0.074 0.477 
Stage 0.371 0.000 0.271 0.007 0.274 0.006 0.300 0.003 0.116 0.253 -0.012 0.907 
Grade 0.284 0.004 0.194 0.054 0.232 0.021 0.278 0.005 0.135 0.184 0.126 0.223 
Size 0.263 0.009 0.290 0.004 0.172 0.090 0.284 0.005 0.220 0.029 0.109 0.294 
Tumor 
Number 
-0.081 0.424 -0.023 0.818 0.004 0.972 0.012 0.903 -0.062 0.544 0.093 0.369 
CIS -0.176 0.082 0.072 0.481 -0.137 0.178 0.046 0.655 0.105 0.302 0.280 0.006 
Primary / 
Recurrent 
-0.120 0.239 -0.273 0.006 -0.037 0.718 -0.229 0.023 0.023 0.824 0.020 0.850 
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CD68
+
 and CD163
+
 macrophages and BCG treatment outcome 
 To evaluate the CD68
+
 and CD163
+
 macrophages infiltration within stroma and 
tumor areas in the context of BCG treatment outcome, counts were stratified based on 
percentiles (25
th
,50
th
,75
th
). The same strategy was applied for the CD163/CD68 ratio. 
(Table 3)  
Regarding CD68 expression, no association was found between the counts and 
treatment outcome. On the other hand we observed that only CD163
+
 stroma counts falling 
within the 25
th
 percentile (>19 macrophages) presented a trend association with treatment 
outcome; CD163
+
 macrophage counts in the stroma were classified as low (LS) or high 
(HS) accordingly. Namely, a higher frequency of patients with BCG failure presented HS 
(above the 25
th
 percentile) for CD163
+
macrophages (83%) when compared with ones 
where BCG was successful (74%); yet this association was not statistically significant. 
We also observed that the LS phenotype was always associated with low 
macrophage tumor counts (LT) (Fig. 4A). Furthermore, the CD163
+
 LS phenotype 
(associated with LT) presented BCG treatment response rates similar to the cases with HS 
and high tumor CD163
+
counts (HT; >75
th
 percentile – Fig. 4B). Based on these 
observations, we decided to merge these two groups (LS/LT and HS/HT) and compare it 
with the cases presenting HS but LT CD163
+
 counts. Taking into consideration the low 
CD163
+
 counts presented by the tumors included in the LT phenotype (<10 macrophages) 
in comparison with the high stroma counts, the group was termed high stroma-predominant 
CD163
+
 macrophage group (HSP, Fig. 4C).  
 
 
 
 
  
 Figure 4 – Immunohistochemical staining showing different grades of CD163+ 
macrophages infiltration in bladder tumors (400x). Representative images (A-C) of macrophages 
stained with anti-CD163 (brown). A- Low Stroma and Low Tumor Macrophages infiltration 
(LS/LT); B- High Stroma and High Tumor Macrophages infiltration (HS/HT); C- High Stroma and 
Low Tumor Macrophages infiltration (HS/LT) – High Stroma-predominant Macrophages Counts. 
C B 
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Table 3 – Relation between the counts of positive macrophages and patients 
 
Variables Total Responders Non-
Responders 
p
* HR [95% CI] p** 
 n (%) n (%) n (%)    
CD68 Stromal       
≤27.8 (25th percentile) 25 (25.3) 17 (29.8) 8 (19.0) 
0.223 
  
>27.8 (25
th 
percentile) 74 (74.7) 40 (70.2) 34 (81.0) 1.875 [0.865-4.064] 0.111 
≤33.4 (50th percentile) 50 (50.5) 29 (50.9) 21 (50.0) 
0.931 
  
>33.4 (50
th 
percentile) 49 (49.5) 28 (49.1) 21 (50.0) 1.219 [0.662-2.242] 0.525 
≤38.4 (75th percentile) 75 (75.8) 42 (73.7) 33 (78.6) 
0.575 
  
>38.4 (75
th 
percentile) 24 (24.2) 15 (26.3) 9 (21.4) 1.209 [0.606-2.412] 0.589 
CD68 Tumor       
≤7.2 (25th percentile) 25 (25.3) 14 (24.6) 11 (26.2) 
0.854 
  
>7.2 (25
th 
percentile) 74 (74.7) 43 (75.4) 31 (73.8) 1.461 [0.689-3.098] 0.323 
≤11.4 (50th percentile) 51 (51.5) 28 (49.1) 23 (54.8) 
0.579 
  
>11.4 (50
th 
percentile) 48 (48.5) 29 (50.9) 19 (45.2) 1.029 [0.558-1.895] 0.928 
≤16.4 (75th percentile) 75 (75.8) 41 (71.9) 34 (81.0) 
0.301 
  
>16.4 (75
th 
percentile) 24 (24.2) 16 (28.1) 8 (19.0) 0.842 [0.389-1.822] 0.663 
CD163 Stromal       
≤19 (25th percentile) 25 (25.3) 17 (29.8) 8 (19.0) 
0.223 
  
>19 (25
th 
percentile) 74 (74.7) 40 (70.2) 34 (81.0) 2.115 [0.972-4.603] 0.059 
≤25.2 (50th percentile) 50 (50.5) 29 (50.9) 21 (50.0) 
0.931 
  
>25.2 (50
th 
percentile) 49 (49.5) 28 (49.1) 21 (50.0) 1.248 [0.680-2.291] 0.475 
≤28.8 (75th percentile) 75 (75.8) 41 (71.9) 34 (81.0) 
0.301 
  
>28.8 (75
th 
percentile) 24 (24.2) 16 (28.1) 8 (19.0) 0.828 [0.382-1.793] 0.631 
CD163 Tumor       
≤2 (25th percentile) 25 (25.3) 13 (22.8) 12 (28.6) 
0.514 
  
>2 (25
th 
percentile) 74 (74.7) 44 (77.2) 30 (71.4) 1.018 [0.520-1.994] 0.958 
≤5.8 (50th percentile) 50 (50.5) 29 (50.9) 21 (50.0) 
0.931 
  
>5.8 (50
th 
percentile) 49 (49.5) 28 (49.1) 21 (50.0) 1.326 [0.719-2.444] 0.366 
≤10 (75th percentile) 75 (75.8) 41 (71.9) 34 (81.0) 
0.301 
  
>10 (75
th 
percentile) 24 (24.2) 16 (28.1) 8 (19.0) 0.890 [0.411-1.927] 0.767 
CD163/CD68 Stromal       
≤40.95 (25th percentile) 25 (25.3) 14 (24.6) 11 (26.2) 
0.854 
  
>40.95 (25
th 
percentile) 74 (74.7) 43 (75.4) 31 (73.8) 1.285 [0.630-2.619] 0.491 
≤54.54 (50th percentile) 50 (50.5) 30 (52.6) 20 (47.6) 
0.622 
  
>54.54 (50
th 
percentile) 49 (49.5) 27 (47.4) 22 (52.4) 1.229 [0.667-2.265] 0.509 
≤62.1 (75th percentile) 75 (75.8) 41 (71.9) 34 (81.0) 
0.301 
  
>62.1 (75
th 
percentile) 24 (24.2) 16 (28.1) 8 (19.0) 0.789 [0.364-1.711] 0.549 
CD163/CD68 Tumor       
≤5 (25th percentile) 28 (28.3) 18 (31.6) 10 (23.8) 
0.396 
  
>5 (25
th 
percentile) 71 (71.7) 39 (68.4) 32 (76.2) 1.567 [0.766-3.203] 0.218 
≤18.8 (50th percentile) 52 (52.5) 31 (54.4) 21 (50.0) 
0.666 
  
>18.8 (50
th 
percentile) 47 (47.5) 26 (45.6) 21 (50.0) 1.318 [0.714-2.433] 0.378 
≤39.1 (75th percentile) 76 (76.8) 43 (75.4) 33 (78.6) 
0.715 
  
>39.1 (75
th 
percentile) 23 (23.2) 14 (24.6) 9 (21.4) 1.026 [0.490-2.148] 0.947 
 
HR: Hazard Ratio; CI: Confidence Interval 
* 
: Chi-square test; 
**
: Wald test 
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This comparison highlighted that a higher percentage of patients presenting BCG 
failure had HSP when compared to the ones where the treatment was successful (69% vs. 
46%; p=0.020; Sensivity: 54.4%; Specifity: 69.1%; Fig. 5). No association was found 
regarding CD163
+
/CD68
+
 ratio and BCG treatment outcome. 
 
 
 
 
 
 
  
  
 Figure 5 – Association between combined CD163+ macrophages counts and BCG 
treatment failure. Higher stroma-restricted CD163
+
 macrophages counts were associated with non-
response after BCG immunotherapy. LS/LT: Low Stromal and Low tumor; HS/HT: High Stromal 
and High Tumor; HS/LT: High Stromal and Low Tumor – High Stroma-predominant Counts. “*” 
p=0.020 (Chi-square Test).  
 
 
 In order to estimate the influence of higher CD163
+
 macrophages counts in terms of 
RFS after BCG treatment, a Kaplan-Meier analysis was performed (Fig. 6). Differences 
were found in terms of RFS between patients with LS and HS counts of CD163
+
 
macrophages (mean RFS: 126 vs. 92 months; log rank, p=0.052; Fig.6A). Moreover, 
patients with HSP CD163
+
 macrophages counts presented a different behavior in terms of 
RFS (log rank, p=0.008; Fig.6B) and a lower RFS (mean: 85 months) than all the others 
(mean:123 months).  
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 Univariate Cox Regression analysis revealed that patients with tumors presenting 
CD163
+
 macrophages HS counts had an increased risk trend for recurrence after treatment, 
(HR=2.115; 95%CI: [0.972-4.603]; p=0.059). Moreover, patients with tumors classified as 
HSP showed a clear 2-fold increased risk of BCG treatment failure (HR=2.343 95%CI: 
[1.197-4.587] p=0,013).  
 
 
 Figure 6 – Effect M2-polarized TAMs in recurrence-free survival (RFS). Kaplan-Meier 
analysis to evaluate the association between RFS in the studied patients and: A- CD163
+
 
macrophages counts in stroma; B- CD163
+
 macrophages combined counts. High Stroma-
predominant counts (HS/LT: High Stromal but Low Tumor Counts) vs. LS/LT (Low Stromal and 
Low Tumor counts) or HT/HT (High Stromal with High Tumor counts). Comparison performed by 
log-rank test (A: p=0.052; B: p=0.008); + censored “Low Counts” or “LS/LT or HS/HT” cases; ♦ 
censored “High Counts” or “High Stroma-predominant Counts (HS/LT)” cases.  
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 To assess the individual effect of CD163
+
 macrophage infiltration in BCG 
treatment outcome, multivariate analysis was performed.  When adjusted to potential 
confounders, such as age and therapeutic scheme, patients with HS CD163
+ 
and HSP 
CD163
+
 counts had more than a 2-fold increased risk of recurrence (respectively, 
HR=2.402 95%CI: [1.211-4.763] p=0.012 and HR=2.627 95%CI: [1.340-5.150] p=0.005; 
Table 4).  
 
 Table 4 – Multivariate analysis and risk estimation of CD163+ macrophages influence on 
BCG therapy outcome. 
 
LS/LT: Low Stromal and Low tumor counts;  
HS/HT: High Stromal and High Tumor counts ;  
HS/LT: High Stromal but Low Tumor counts; 
HR: Hazard Ratio; CI: Confidence Interval 
a adjusted for age and BCG schedule 
 
 
CD163
+
 Macrophages and expression of HIF-1α  
The association between CD163
+
 macrophages counts within tumor and hypoxia 
was evaluated based on HIF-1α expression. The expression of HIF-1α is represented by a 
nuclear and cytoplasmic staining at the invasive front of the tumor. It was also observed 
that tumor areas with high density of CD163
+
 macrophages expressed high amounts of 
HIF-1α (Fig. 7A&B). On the other hand, tumor areas with low CD163+ macrophages 
counts, independently of the counts in the stroma, presented lower expression of HIF-1α 
(Fig. 7C&D). In resume, while the HSP and LS (that also present LT counts) phenotypes 
were associated with tumors showing low degree of hypoxia, samples presenting the 
HS/HT phenotypes are associated with highly hypoxic tumors (p<0.001). However, the 
expression of HIF-1α was not associated with BCG treatment outcome.  
CD163
+
 macrophages HR
a 
95%CI p value 
Stromal Counts    
Low (≤19)  1.0 Referent  
High (>19)  2.402
 
1.211-4.763 0.012 
    
Combined Counts    
LS/LT or HS/HT 1.0 Referent  
High Stroma-predominant Counts 
(HS/LT)  
2.627
 
1.340-5.150 0.005 
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 Figure 7 – Immunohistochemical staining showing different grades of CD163+ 
macrophages infiltration and HIF-1α in the tumor nest of bladder cancer (100x). Representative 
images (A and C) of Macrophages stained with anti-CD163 (brown) and the same areas stained 
with anti-HIF-1α (brown - B and D). A- High infiltration of CD163+ Macrophages in tumor; B- 
High staining of HIF-1 α in tumor; C- Low infiltration of CD163+ Macrophages in tumor; D- Low 
staining of HIF-1 α in tumor; 
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Discussion 
 Although BCG immunotherapy is the primary treatment option for 
intermediate/high risk bladder tumors, the failure rate is over 30%.(1) Therefore the 
identification of biomarkers able to predict treatment failure and to provide an early 
identification of those patients better served by alternative therapies is crucial for the 
management of this disease.(4) There are some biomarkers emerging in the literature, but at 
the moment none could be set as reliable to translate into clinical practice.(21, 22)  
 One of the biomarkers with consistent results was the presence of TAMs in bladder 
tumors prior to BCG treatment, although more studies are needed to validate its relevance. 
(10-12, 21, 22) On the other hand, the marker used was CD68, a lineage marker found in both 
M1 and M2 macrophages.(7) Several authors showed that in order to accurately determine 
TAMs influence in prognosis and treatment outcome, M2-specific markers, such as 
CD163, should be used.(23-26) To address this subject we investigated the influence of 
TAMs (CD68
+
) and also the M2-polarized macrophage phenotype (CD163
+
), in the 
context of BCG treatment outcome. Taking into consideration that the microenvironment 
plays a determinant role in the modulation of the macrophage lineages we evaluated 
independently the tumor and the stroma. 
 We started by seeking associations between the patient’s clinicopathological 
characteristics and the BCG treatment outcome and found that it was influenced by age and 
treatment scheme (iBCG, mBCG). Therefore, these variables were considered potential 
confounders and were taken into account in multivariate analysis models to assess the 
TAMs influence in BCG outcome. We also observed that CD68
+
 and CD163
+
 
macrophages counts in both the stroma and tumor were correlated with higher stage, grade 
and tumor size. Similar results were observed by other authors for bladder cancer using 
CD68.(12, 27) The CD163
+ 
macrophages identification has also been associated with poor 
prognosis in several types of cancer (23, 28); however this is the first study suggesting that 
the M2-subtype may be a characteristic of high-risk of recurrence/progression bladder 
tumors.   
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Three studies have been presented supporting the idea that a higher density of 
macrophages in the tumor and its surroundings may be associated with BCG treatment 
failure.(10-12) However, we observed no associations between CD68
+
 macrophage counts in 
stroma and in tumor nests and the outcome. Even though contradictory these results may 
stem from the fact that two of this studies were conducted in a low number of samples (27 
and 46) and did not take into consideration the localization of the macrophages. A third 
study involving a localization-based analysis in CIS, described that cases with a low 
density of tumor CD68
+
 macrophages presented higher recurrence-free rate. However the 
reduced number of CIS in our series does not allow an accurate comparison. Nevertheless, 
whether macrophage density influences treatment outcome in different ways depending on 
the histology of the tumor warrants a deeper evaluation.    
Contrastingly, we observed that a high density of M2-polarized macrophage counts 
in the stroma but not in the tumor related with BCG treatment failure.  Interestingly, cases 
presenting a high density of macrophages in the tumor presented a more favourable 
outcome. Furthermore, these cases behaved similarly to those presenting an overall low 
density of M2 macrophages (LT/LS). These results suggest that M2-macrophages may be 
influencing treatment outcome in different ways possibly due to the influence of 
differentiated micro environmental stimuli in the stroma and the tumor.  
 Since TAMs may be found in vascularised stroma but also significantly 
accumulate in hypoxic areas within the tumor [19, 29, 30], we hypothesized that 
differences in CD163 expression between tumor areas could be the result of hypoxia. This 
was confirmed by the association between high tumor CD163
+
 macrophage counts and 
high expression of the hypoxia marker HIF-1α within tumor areas; conversely, in 
specimens with High stroma-predominant CD163
+
 counts (and respectively low tumor 
counts), HIF-1α expression within tumor areas was low. These observations suggest that 
hypoxic conditions may dictate the accumulation of CD163
+
 macrophages in bladder 
tumor areas.  
Hypoxia not only seems to dictate the accumulation of macrophages in the tumor 
but may also modulate the M2-macrophage phenotype. In particular, hypoxia is known to 
enhance the expression of angiogenic factors, producing high amounts of VEGF and other 
proinflammatory cytokines like TNF-α, IL-1β, MIF and COX2 that act as promoters of a 
Th1 mediated response known to favour BCG action [19]. On the other hand, normoxia 
may favour the M2 immunosuppressive phenotype and the downregulation of molecules 
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implicated in immunological activation such as IL-12, IL-18, IL-1β and TNFα [5]. This 
selective pressure also upregulates the expression of Th2-type cytokines, as well as IL-10, 
IL-1RA and TGF-β, some of which have been associated with a lack of response to BCG 
treatment [16]. Based on these observations we hypothesize that hypoxic conditions may 
favour the accumulation of M2-polarized macrophages in the tumor and also promote their 
angiogenic phenotype, ultimately leading to a better treatment outcome. Conversely, non-
hypoxic or low-hypoxic conditions (low HIF-1α) decrease the density of macrophages in 
the tumor area, maintaining them in the stroma area. We may hypothesize that these 
macrophages present the immunosuppressive phenotype, which in part may explain the 
higher treatment failure.  
Although our results point out that high stroma-predominant CD163
+
 macrophage 
counts is a good predictor of recurrence after BCG treatment, some limitations need to be 
overcome in order to use this biomarker in clinical practice. Namely, efforts should be 
taken to make the macrophage counts reproductive. It would be important to evaluate 
different counting methodologies, especially involving image acquisition and automatic 
counting software in order to create a standard technique and cut-off values. Also, this a 
preliminary study with 99 patients that requires validation in larger series and different 
cohorts. A careful evaluation of the influence of hypoxia and other microenvironment 
factors in the modulation of macrophage phenotypes is also needed in this context.  
 Altogether, our results indicate that discrimination of M2 macrophages (CD163
+
) is 
a better indicator of treatment failure than the overall macrophage counting given by 
CD68. Moreover, our observations suggest that only M2 macrophages under normoxic 
conditions may exert an inhibitory effect on BCG immunotherapy, possibly due to its 
immunosuppressive phenotype.  
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Conclusion and Future Perspectives 
 
From this study we can conclude that subtype M2 macrophages (CD163
+
) is a 
better indicator of treatment failure than the counts of overall macrophage and indicates 
that M2 macrophages under normoxic conditions may exert an inhibitory effect on BCG 
immunotherapy, possibly due to its immunosuppressive phenotype. 
There remain no doubts that macrophages have a major importance in tumor 
development. Depending on the mode of activation, macrophages can promote or suppress 
tumors. The tumor microenvironment is one of the most important factors to take into 
account in the interaction of macrophages with tumor cells. 
It is important to reproduce the same study with a larger population as well as 
making the macrophages counts reproducible for example by using an automated count 
software. In the further studies will be important to assess in more detail the importance of 
hypoxia in the modulation of macrophage or other microenvironmental factors. Evaluate 
what exact cytokines (IL-10, VEGF) from tumor intervening in the role of TAMs, what 
way can they trigger your response, its location in the tumor and whether can be targeted 
for therapeutic strategies. 
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